NCT05289492

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Study of EOS884448 Alone, and in Combination with Iberdomide with or Without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: iTeos Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	EOS884448	EOS884448 will be administered in arm A,B and C
DRUG	Iberdomide	Iberdomide will be administered in arm B and C
DRUG	Dexamethasone	Dexamethasone will be administered in arm C

Timeline

• Start date: 2022-05-01
• Primary completion: 2023-11-29
• Completion: 2023-11-29
• First posted: 2022-03-21
• Last updated: 2024-10-26

Locations

13 sites across 4 countries: United States, Belgium, France, Spain

Regulatory

• FDA-regulated drug study